Mylenda 0.25 mg/0.5 ml SC Injection contains Semaglutide 0.25 mg/0.5 ml. It is a glucagon-like peptide-1 (GLP-1) receptor agonist medicine used to improve blood glucose control in adults with type 2 diabetes mellitus and to support weight management in appropriate patients.
Uses:
-
Treatment of type 2 diabetes mellitus.
-
Helps reduce high blood glucose levels.
-
Used along with diet and exercise to improve glycemic control.
-
Helps reduce the risk of cardiovascular events in certain patients with type 2 diabetes and cardiovascular risk factors.
-
Supports weight management in suitable patients.
Dose:
-
Adults: Usually started with 0.25 mg once weekly by subcutaneous injection for the first 4 weeks, followed by dose adjustment as directed by a physician.
-
Inject under the skin of the abdomen, thigh, or upper arm as instructed by a healthcare professional.
-
Dose and duration depend on the patient's medical condition, blood glucose levels, and response to treatment.
-
Use the medicine exactly as prescribed by a healthcare professional.